Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Selventa Strengthens Intellectual Property for SysDx™ Approach to Personalized Medicine

Published: Thursday, May 09, 2013
Last Updated: Thursday, May 09, 2013
Bookmark and Share
Patent is core to Selventa’s SysDx™ approach to mining and comparing biological data for predicting a patient’s response or non-response to a drug.

“We are very pleased to gain this important intellectual property protection that strengthens our SysDx approach to understanding a patient’s disease and predicting response or non-response to a therapy,” said David de Graaf, CEO of Selventa. “This patent is a significant step forward in the development of SysDx tests in multi-factorial diseases such as rheumatoid arthritis, IBD, and cancer. It also strengthens our leadership position in analyzing ‘big data’ molecular information to identify patient disease-relevant biomarkers.”

A major differentiator of SysDx tests is their ability to incorporate and analyze ALL relevant molecular information in a disease, across thousands of patients, to identify biomarkers that are linked to disease-driving mechanisms.

“In order to deliver true personalized medicine, physicians will require diagnostics that holistically integrate and interpret multiple types of biological data. SysDx tests consist of biomarkers that are selected through a rigorous biomarker analysis of a patient’s biological map derived from large, multi-omic data sets that can include genomic, epigenomic, transcriptomic, proteomic, metabolomic, electronic medial record information. This comprehensive analysis is then used to generate a clinically-relevant diagnostic report that physicians and patients can use to make an optimal treatment decision,” concluded de Graaf.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selventa Developing Powerful New Class of Multi-omic Based Diagnostic Test
This powerful new class of diagnostic test will accelerate the implementation of personalized healthcare.
Friday, February 01, 2013
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos